Medexus Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA58410Q2036
CAD
2.74
0.06 (2.24%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Medexus Pharmaceuticals, Inc. stock-summary
stock-summary
Medexus Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc, is a Canada-based company engaged in pharmaceutical business sector. The Company is a North American focused, specialty pharmaceutical business that operates through three segments: Medac Pharma USA, a fully integrated commercial infrastructure focused on auto-immune diseases in the United States; Medexus Pharma Canada, a fully integrated commercial infrastructure focused on auto-immune disease and pediatric diseases in Canada; and a Business Development function, which works to maintain its product pipeline. The Company's flag products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an allergy medication. The Company provides products for the healthcare professionals and patients.
Company Coordinates stock-summary
Company Details
225-1 du Commerce Pl , VERDUN QC : H3E 1A2
stock-summary
Tel: 1 514 76226261 905 3303275
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Peter Van der Velden
Independent Chairman of the Board
Mr. Kenneth D'Entremont
Chief Executive Officer, Director
Mr. Benoit Gravel
Independent Director
Ms. Adele Gulfo
Independent Director
Mr. Michael Mueller
Independent Director
Mr. Stephen Nelson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
34 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 92 Million (Micro Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.24

stock-summary
Return on Equity

6.27%

stock-summary
Price to Book

1.28